Evidence map›Paper›PMID 33751108›Full record

ArticleBlood2021

miR-15a/16-1 deletion in activated B cells promotes plasma cell and mature B-cell neoplasms.

Tomasz Sewastianik, Juerg R Straubhaar, Jian-Jun Zhao, Mehmet K Samur, Keith Adler, Helen E Tanton, Vignesh Shanmugam, Omar Nadeem, Peter S Dennis, Vinodh Pillai and 15 more

Open access · bronzeAbstract read
In one paragraph

Article in Blood, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Potential Use of MicroRNA Technology in Thalassemia Therapy.Journal of clinical medicine research · 2024
    Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Complete miRNA-15/16 loss in mice promotes hematopoietic progenitor expansion and a myeloid-biased hyperproliferative state.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  13. Article
  14. Article
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 4 institutions in 2 countries.

Tomasz SewastianikDepartment of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Juerg R StraubhaarFAS Informatics, Harvard University, Cambridge, MA.
Jian-Jun ZhaoDepartment of Medical Oncology and.
Mehmet K SamurDepartment of Medical Oncology and.
Keith AdlerDepartment of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Helen E TantonDepartment of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Vignesh ShanmugamDepartment of Pathology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA.
Omar NadeemDepartment of Medical Oncology and.
Peter S DennisDepartment of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Vinodh PillaiDepartment of Pathology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA.
Jianli WangDepartment of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Meng JiangDepartment of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Jianhong LinDepartment of Medical Oncology and.
Ying HuangDepartment of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Daniel BrooksCenter for Advanced Orthopedic Studies, Beth Israel-Deaconess Medical Center, Harvard Medical School, Boston, MA.
Mary BouxseinCenter for Advanced Orthopedic Studies, Beth Israel-Deaconess Medical Center, Harvard Medical School, Boston, MA.
David M DorfmanDepartment of Pathology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA.
Geraldine S PinkusDepartment of Pathology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA.
Davide F RobbianiLaboratory of Molecular Immunology, Rockefeller University, New York, NY.
Irene M GhobrialDepartment of Medical Oncology and.
Bogdan BudnikMass Spectrometry and Proteomics Resource Laboratory, FAS Division of Science, Harvard University, Cambridge, MA; and.
Petr JarolimDepartment of Pathology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA.
Nikhil C MunshiDepartment of Medical Oncology and.
Kenneth C AndersonDepartment of Medical Oncology and.
Ruben D CarrascoDepartment of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Harvard University · USBrigham and Women's Hospital · USBeth Israel Deaconess Medical Center · USRockefeller University · US

Funding

Targeting Genomic Instability and Evolution in MyelomaP01CA155258 · NCI · DANA-FARBER CANCER INST · PI Jill Corre · 2011 to 2026
$32.5M
Validating the eCyPA/CD147 signaling complex for myeloma therapyR01CA196783 · NCI · DANA-FARBER CANCER INST · PI CARRASCO, RUBEN D · 2015 to 2019
$2.0M
Elucidating the role of microRNAs in the initiation of multiple myelomaR00CA172292 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI ZHAO, JIANJUN · 2015 to 2017
$747k
NCI NIH HHS P01 CA155258NCI NIH HHS R00 CA172292NCI NIH HHS R01 CA196783
6 · The paper itself

Abstract

Chromosome 13q deletion [del(13q)], harboring the miR-15a/16-1 cluster, is one of the most common genetic alterations in mature B-cell malignancies, which originate from germinal center (GC) and post-GC B cells. Moreover, miR-15a/16 expression is frequently reduced in lymphoma and multiple myeloma (MM) cells without del(13q), suggesting important tumor-suppressor activity. However, the role of miR-15a/16-1 in B-cell activation and initiation of mature B-cell neoplasms remains to be determined. We show that conditional deletion of the miR-15a/16-1 cluster in murine GC B cells induces moderate but widespread molecular and functional changes including an increased number of GC B cells, percentage of dark zone B cells, and maturation into plasma cells. With time, this leads to development of mature B-cell neoplasms resembling human extramedullary plasmacytoma (EP) as well as follicular and diffuse large B-cell lymphomas. The indolent nature and lack of bone marrow involvement of EP in our murine model resembles human primary EP rather than MM that has progressed to extramedullary disease. We corroborate human primary EP having low levels of miR-15a/16 expression, with del(13q) being the most common genetic loss. Additionally, we show that, although the mutational profile of human EP is similar to MM, there are some exceptions such as the low frequency of hyperdiploidy in EP, which could account for different disease presentation. Taken together, our studies highlight the significant role of the miR-15a/16-1 cluster in the regulation of the GC reaction and its fundamental context-dependent tumor-suppression function in plasma cell and B-cell malignancies.

Indexed as

AnimalsB-LymphocytesChromosome DeletionChromosome DisordersChromosomes, Human, Pair 13Gene DeletionGene Expression Regulation, NeoplasticHumansLymphoma, Large B-Cell, DiffuseMiceMice, Inbred C57BLMicroRNAsMultigene FamilyMultiple MyelomaNeoplasms, Plasma CellPlasma CellsMicroRNAsMIRN15 microRNA, humanMirn15 microRNA, mouseMIRN16 microRNA, humanMirn16 microRNA, mouse

Identifiers

PMID33751108
PMCPMC8033455
OpenAlexW3126959040

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.